Is the default mode network the 'ego'?

Not really. The DMN is associated with self-referential thinking, autobiographical memory, and mind-wandering, so the analogy gets used a lot in psychedelic writing. But equating the DMN with the ego is a stretch the data does not fully support. The DMN is a measurable network of brain regions. The ego is a psychological construct. They overlap in interesting ways, and that is about as far as the imaging actually takes us.

Why does quieting the default mode network help depression?

In depression, the DMN tends to be stuck in self-critical, ruminative loops. The same negative thoughts replay, and the network that hosts them is unusually hyperconnected. Research suggests that a temporary loosening of DMN connectivity gives patients room to form new patterns rather than fall back into the same grooves. It is less about silencing thought and more about breaking a stuck pattern long enough that something else can take hold.

Does Spravato do the same thing to the default mode network?

Likely yes in broad strokes. Esketamine, the active ingredient in Spravato, acts on the same NMDA receptor system as racemic IV ketamine, and most clinicians expect similar downstream effects on the DMN. Direct head-to-head fMRI studies comparing the two are limited, so we cannot say the imaging signature is identical. The mechanism is shared; the precise quantitative match has not been fully established.

Will I feel my default mode network going quiet during a ketamine infusion?

Many patients describe it as the rumination tape stopping, or as a quieting of the inner critic that they had not realized was constant. Others describe it more as a sense of distance from their usual thoughts. Not everyone notices it, and the imaging changes do not perfectly track the felt experience. Some patients have a strong subjective shift; others feel little during the session and notice the difference in the days that follow.

Does the effect on the default mode network last?

Acute changes in DMN connectivity are clear in the imaging literature. Longer-term DMN remodeling is less established and remains an active area of research. Most clinicians think about ketamine as opening a window of plasticity in which therapy and behavior change can stick, rather than producing a permanent rewiring on its own. That is why integration work and lifestyle changes during the response window matter so much.

Ketamine and the Default Mode Network: What the Brain Imaging Actually Shows

What the default mode network actually does

The default mode network is a cluster of brain regions that becomes more active when you stop paying attention to the outside world. It includes the medial prefrontal cortex, the posterior cingulate cortex, parts of the parietal lobe, and the hippocampus. Researchers first noticed it as a kind of accident: it kept showing up as the network that quieted down whenever subjects in a scanner were asked to do a task, and lit back up the moment the task ended.

That pattern gave it its name. The DMN is what the brain defaults to when nothing in particular is happening. Mind-wandering. Self-referential thought. Replaying yesterday. Imagining tomorrow. Quietly asking yourself how you are doing. It is not a useless network—it is doing real work—but its work is internal, autobiographical, and tightly tied to the sense of self.

For a healthy person, the DMN cycles in and out as needed. You think about yourself for a while, then a task comes up, the network quiets, and another network takes over. For people stuck in depression and chronic rumination, that handoff is broken. The DMN dominates. The internal monologue does not pause when it should.

Why the DMN matters in depression and rumination

A large body of fMRI work has shown that the DMN is hyperconnected in major depression. Within-network connectivity is elevated, meaning the regions of the DMN talk to each other more tightly and synchronously than they do in healthy controls. Outwardly, this is what rumination feels like: the same thoughts looping with unusual stickiness, the inner critic with unusual volume, an inability to break out of a self-focused frame.

Patients with treatment-resistant depression often describe a particular flavor of this. It is not just sadness. It is a felt inability to stop replaying, second-guessing, and re-narrating one's own life—an exhausting, glued-on relationship with the self. That phenomenology lines up with the connectivity data in a way that few brain-imaging findings in psychiatry actually do. Connect this to treatment-resistant depression patterns and the picture sharpens further: many of the same patients who fail conventional antidepressants are the ones with the most hyperconnected DMNs.

This is why the DMN became one of the most-studied targets in the search for novel antidepressants. If you could loosen the network's grip—temporarily, safely—you might give patients an exit from the loop.

Scheidegger 2012 and the first clear DMN signal

The cleanest early evidence came from Scheidegger and colleagues in 2012, in a study published in PLOS One. The team gave 19 healthy volunteers a single sub-anesthetic infusion of S-ketamine and scanned their resting-state brain activity 24 hours later. The 24-hour window matters: that is when ketamine's antidepressant effect tends to peak in clinical samples, even though the drug itself has long since cleared.

The finding was specific. DMN connectivity to the dorsal nexus, the pregenual anterior cingulate cortex, and the medial prefrontal cortex was significantly reduced compared to placebo. These are precisely the hubs that prior work had implicated in depressive rumination. The same network that is glued together in depression had been demonstrably loosened a full day after a single ketamine dose.

It was one of the first imaging studies to show, mechanistically, that ketamine's antidepressant story was not just a glutamate-and-BDNF story. It was also a network-level story—a measurable shift in how large-scale brain regions coordinate.

Ketamine is FDA-approved as an anesthetic; its use for depression and other psychiatric indications is off-label. Esketamine, the related compound marketed as Spravato, is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation.

Niesters and the resting-state connectivity work

A second 2012 study, by Niesters and colleagues in Anesthesiology, looked at resting-state functional connectivity during and shortly after a sub-anesthetic ketamine infusion in healthy volunteers. The team found that ketamine altered connectivity in regions tied to pain and affective processing, with reductions in connectivity that mirrored the regions implicated in chronic pain hypersensitivity and mood dysregulation.

Niesters' work matters because it bridges the depression literature with the chronic pain literature. The same NMDA-mediated network changes that may quiet rumination in depression appear to quiet the kind of self-referential pain amplification that shows up in central sensitization. This connection is part of why ketamine is studied in both depression and chronic pain syndromes—the underlying glutamate-and-network biology is shared.

Together, Scheidegger and Niesters established a basic claim that has held up reasonably well: a single sub-anesthetic ketamine dose produces measurable resting-state network changes in humans, and those changes overlap with the networks implicated in the conditions ketamine seems to help.

How this fits with Carhart-Harris's entropic brain framework

Robin Carhart-Harris and colleagues, in a widely cited 2014 paper in Frontiers in Human Neuroscience, proposed the entropic brain hypothesis. The idea is that ordinary waking consciousness is an unusually constrained, low-entropy state, and that "primary" states—dreaming, early childhood, psychedelic experience—involve a temporary collapse of that tight organization. The DMN, in this framework, is one of the structures most associated with the constrained state.

A follow-up 2017 study by Schartner, Carhart-Harris and colleagues in Scientific Reports measured spontaneous MEG signal diversity under psychoactive doses of ketamine, LSD, and psilocybin. All three drugs increased signal diversity above the normal waking baseline, suggesting they all loosen the same kind of organized brain dynamics. Ketamine, in this view, is part of a family of compounds that produce a temporary dis-organization of dominant network patterns—and the DMN is near the center of that dis-organization.

This framework helps explain something patients often describe but is hard to pin down clinically: a felt loosening of the rumination loop, sometimes during the session, more often in the days that follow. The imaging matches what they say.

What patients describe vs. what the scans show

It is worth being precise here, because the popular framing tends to overshoot. The scans show reduced DMN connectivity at specific time points after a sub-anesthetic dose. They do not show the DMN being "turned off." They do not show a permanent rewiring. They show a measurable, time-limited loosening that overlaps with the period of antidepressant response.

Patient descriptions vary widely. Some report a striking quiet during or after the session—an unfamiliar break from the inner monologue, a felt distance from their usual narrative about themselves. Others describe little subjective change in the moment but notice over the following week that the rumination tape has lost some of its grip. A minority do not notice much at all. The imaging data and the felt experience correlate loosely, not tightly. Dissociation during a ketamine session is part of this picture for some patients but not all, and the imaging signature does not require a strong dissociative experience to appear.

The honest summary is that ketamine produces a real network-level change, that change overlaps with the period of clinical benefit, and the subjective experience is one of several windows onto that change rather than a perfect mirror of it.

What we tell patients about quieting the DMN

When patients come to Music City Ketamine asking specifically about the DMN—and they do, more than they used to—we try to be careful about what the data actually supports. We say that the imaging is real. We say that the loosening is temporary. We say that the most useful way to think about ketamine is as a treatment that opens a window of plasticity in which therapy, behavior change, and new patterns can take hold. The drug does not do the rewiring on its own.

We also remind patients that ketamine is not for everyone, and that the network-level response is not universal. Some people do not respond. Some respond modestly. Some have a strong response that lasts weeks; others need maintenance infusions to sustain the benefit. Cost is a real consideration—at our clinic, infusions are $475 per session, and insurance does not typically cover off-label use.

Marla Peterson, CRNA, oversees every infusion, with anesthesia-level monitoring and a CRNA in the room throughout the session. The clinical setting matters because the goal is not just a network shift; the goal is a network shift that happens safely, with the right monitoring, and with a plan for what comes after. The neuroplastic window only matters if you do something with it.

If you have read about ketamine brain research or how ketamine works at the receptor level and want to understand how the receptor story connects to the network story, the DMN findings are a good place to look. They are some of the most reproducible imaging results in the entire ketamine literature, and they help explain why patients describe what they describe.